Market outlook of the psoriatic arthritis market
Psoriatic arthritis is a chronic inflammatory disease that affects the distal joints in the body and may also affect the back and sacroiliac joints of the pelvis. The global market for psoriatic arthritis is expected to witness moderate growth during the forecast period and factors like the increase in penetration of biologic therapies are expected to augment the prospects for growth in this market. Additionally, the recent launch of products like Otezla and Stelara is also expected to boost market growth during the forecast period, resulting in its moderate CAGR of nearly 5% by 2019.
In this market research report, Technavio analysts estimate the Americas to account for more than 40% of the total market share by 2019. High market dominion of this region can be attributed to factors such as the increase in public awareness and the growing preference for biologic drugs.
Segmentation by mechanism of action and analysis of: TNF inhibitors, PDE4 inhibitors, & interleukin blockers
The TNF inhibitors aid in suppressing the inflammatory response in the patient's body. These inhibitors are used to manage diseases like rheumatoid arthritis, psoriatic arthritis, psoriasis, inflammatory bowel disease, and seronegative spondyloarthropathies. Moreover, its ability to use a targeted mechanism to treat most of the inflammatory and autoimmune diseases is primarily responsible for its high market share of almost 80% by 2019.
The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -
Technavio Announces the Publication of its Research Report – Global Psoriatic Arthritis Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Psoriatic Arthritis Market: Hoffmann-La Roche, Eli-lilly, Sanofi and Otsuka Holdings
Other Prominent Vendors in the market are: Novartis, Amgen, Boston Biomedical, AROG Pharmaceuticals, ARIAD Pharmaceuticals, Roche, Merck, Eli Lilly, AB Science, Galena Biopharma, AstraZeneca, Taiho Oncology, Samumed, Ipsen Biopharmaceuticals, Eddingpharm, Tekmira Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, ASLAN Pharmaceuticals, Five Prime, Array Biopharma, BIND Therapeutics, Boehringer Ingelheim, Daiichi-Sankyo, Bayer HealthCare, and Celgene.
Commenting on the report, an analyst from Technavio’s team said: “Some emerging trends are expected to boost the global psoriatic arthritis market. The dominance of the market by biologics in the treatment of psoriatic arthritis patients is one such trend. It is expected that biologics will be the preferred treatment option of the medical profession as well as the patients themselves. This will increase the number of treatment-seeking patients and result in an increase in the overall consumption of drugs for this condition.”
According to the report, the global psoriatic arthritis market is driven by several factors. The presence of growing unmet needs for appropriate drugs is one of the major factors propelling the growth of the market.
Further, the report states that many branded drugs present for the treatment of psoriatic arthritis are soon going to lose their patent protection. Expiry of patents results in the loss of exclusivity of that specific drug, leading to a rapid decline in its sales. Therefore, this is expected to have a negative impact on the revenue of the branded drugs used to treat psoriatic arthritis.
Hoffmann-La Roche, Eli-lilly, Sanofi, Otsuka Holdings, Novartis, Amgen, Boston Biomedical, AROG Pharmaceuticals, ARIAD Pharmaceuticals, Roche, Merck, Eli Lilly, AB Science, Galena Biopharma, AstraZeneca, Taiho Oncology, Samumed, Ipsen Biopharmaceuticals, Eddingpharm, Tekmira Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, ASLAN Pharmaceuticals, Five Prime, Array Biopharma, BIND Therapeutics, Boehringer Ingelheim, Daiichi-Sankyo, Bayer HealthCare, Celgene.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook